More Elephant
In this conversation with Dr. Ella Fung and Dr. Nancy Schoenbrunner, co-founders of Rosalind Dx, we explore what happens when scientific rigor, lived experience, and a bold entrepreneurial leap collide around one simple but powerful idea: access. Rosalind Dx is reimagining prenatal testing by moving it from complex, centralized genome sequencing to a faster, more affordable PCR-based approach. The result? A potential step-change in how non-invasive prenatal testing is delivered, who can access it, and how quickly families receive answers. Ella takes us from Hong Kong to Cambridge to Oxford and into the deeply personal moment of navigating her own pregnancies, where she experienced firsthand how insurance coverage can determine access to critical information. Nancy shares the origin story that begins not in a boardroom, but with a dream, a whiteboard sketch, and decades of experience working alongside the inventors of PCR at Roche. We talk about the leap from industry to startup life, the realities of fundraising as female founders, and why decentralizing advanced diagnostics could be one of the most important shifts in global women’s health. This is a conversation about science, yes. It is also about equity, courage, and the willingness to build something new when the system doesn’t serve everyone equally. If you are interested in and care about the future of healthcare, about designing for access instead of exclusivity, and what it really takes to move from breakthrough idea to commercial reality, this is a must listen. Key More Elephant Takeaways in this Episode: * Rosalind Dx is leveraging PCR technology to replace expensive, centralized genome sequencing with a faster, lower-cost, and more scalable approach to non-invasive prenatal testing. * Access to prenatal diagnostics is not just a medical issue. It is an equity issue. Insurance coverage and geography currently determine who receives the most accurate information during pregnancy. * Decentralizing testing from a handful of global sequencing hubs to regional labs can dramatically reduce cost, turnaround time, and systemic inefficiency. * Female-led innovation in women’s health is gaining momentum, particularly in ecosystems that intentionally address historic funding bias. * and more…
42 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de More Elephant!